Mina Habibizadeh

Mina Habibizadeh

Auto-generated profile, based on publicly available information

Mina Habibizadeh

Regenerative Medicine Research Center Health Technology Institute, Kermanshah University of Medical Sciences Kermanshah Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
MHMina Habibizadeh
Mina Habibizadeh
SNSamad Nadri
Samad Nadri
AFAli Fattahi
Ali Fattahi
KRKobra Rostamizadeh
Kobra Rostamizadeh
PMParvin Mohammadi
Parvin Mohammadi
NFNarges Forouzideh
Narges Forouzideh

29 July 2024 in Tissue Engineering Part B: Reviews
Verified
Journal Article
Closed access
MHMina Habibizadeh
Mina Habibizadeh
PMParvin Mohammadi
Parvin Mohammadi
RARoshanak Amirian
Roshanak Amirian
MMMohammadmehdi Moradi
Mohammadmehdi Moradi
MMMasoud Moradi
Masoud Moradi
The urethra reconstruction using tissue engineering is a promising approach in clinical and preclinical studies in recent years. Generally, regenerative medicine comprises cells, bioactive agents, and biomaterial scaffolds to reconstruct tissue. For the restoration of extended urethral injury are incorporated autologous grafts or flaps from the skin of the genital area and buccal mucosa are utilized. However, biomaterial grafts with cells or growth factors are investigated to enhance these grafts natural and synthetic biomaterials were investigated for pre-clinical studies in the form of decellularization tissues, nanofiber/ microfiber, film, and foam grafts that determined safety and efficiency. In this regard, skin grafts, bladder epithelium, buccal mucosa, small intestinal submucosa, tissue-engineered buccal mucosa, and polymeric nanofibers in clinical trials were examined, and promising and diverse outcomes were acquired. Even though, one of the challenges of the reconstruction of the urethra is resistance to urine pressure and its ability to be sutured, which could be solved by the proper adjustment of the physicochemical characteristics of the graft. Urethra engineering faces challenges due to necrosis caused by a lack of angiogenesis and fibrosis, which require further investigation in future studies.

27 May 2026 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PMParvin Mohammadi
Parvin Mohammadi
MHMina Habibizadeh
Mina Habibizadeh
MMMohammadmehdi Moradi
Mohammadmehdi Moradi
AKAmir Kiani
Amir Kiani
FGFarjam Goudarzi
Farjam Goudarzi
MMMahmoudreza Moradi
Mahmoudreza Moradi

7 October 2026 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PMParvin Mohammadi
Parvin Mohammadi
MHMina Habibizadeh
Mina Habibizadeh
ZIZhila Izadi
Zhila Izadi
KMKamran Mansouri
Kamran Mansouri
MMMahmoudreza Moradi
Mahmoudreza Moradi

15 July 2026 in Journal of Reports in Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
ZSZahra Samadi
Zahra Samadi
RYRoshanak Yadegarazari
Roshanak Yadegarazari
MHMina Habibizadeh
Mina Habibizadeh
NNNasser Nikfarjam
Nasser Nikfarjam
SMSoheila Mohammadi
Soheila Mohammadi
OTOmid Tavallaei
Omid Tavallaei
Background: The global rise in cancer incidence underscores the urgent need for novel and more effective therapeutic strategies. Among emerging modalities, gene therapy offers a powerful and precise approach by directly modulating genetic pathways involved in tumor growth. However, the success of gene therapy depends critically on the development of safe, efficient, and target-specific carriers capable of condensing, protecting, and delivering nucleic acids to cancer cells with minimal toxicity. Objectives: This study aimed to develop and characterize a novel, biocompatible nanocarrier system based on graphene oxide quantum dots (GOQDs) functionalized with polyethylenimine (PEI) and hyaluronic acid (HA) for potential CD44-targeted gene delivery applications. Methods: The GOQD/PEI/HA nanocarrier was synthesized by covalent conjugation using EDC/NHS chemistry and characterized by Fourier transform infrared spectroscopy (FT-IR) and thermogravimetric analysis (TGA), which confirmed successful functionalization. DNA-binding and condensation were assessed by agarose gel retardation, and field-emission scanning electron microscopy (FE-SEM) was used to determine the size and surface morphology of the prepared complexes. Finally, hemocompatibility and cytocompatibility were evaluated using hemolysis test and MTT assay in HeLa cells. Results: TGA and FT-IR analyses confirmed the successful preparation of functionalized GOQD/PEI/HA NPs. The gel retardation assay demonstrated complete plasmid DNA (pDNA) condensation at a 1:2 pDNA-to-carrier ratio, confirming a strong electrostatic interaction between the DNA and the carrier. Hemolysis rates remained below 2% at all tested concentrations, demonstrating the high hemocompatibility of the carriers. Moreover, MTT assay results showed that HA conjugation significantly increased cell viability from approximately 76% for GOQD/PEI to above 90% for GOQD/PEI/HA, indicating a substantial reduction in GOQD/PEI-associated cytotoxicity. Conclusions: Collectively, these findings confirm that the covalently HA-modified GOQD/PEI nanocarrier effectively integrates strong gene-condensation capability with excellent biocompatibility and hemocompatibility. This system represents a promising and safe nonviral platform with the potential for targeted gene delivery to CD44-positive HeLa cancer cells. Future studies should assess its therapeutic efficacy in more physiologically relevant models, including 3D tumor spheroids, organoid cultures, and in vivo systems, to validate its potential for advanced cancer gene therapy applications.